US President Donald Trump's sweeping executive order imposing 100% tariffs on select pharmaceutical imports took effect this week, creating urgent challenges for Asian manufacturers. The measure targets patented medications and active pharmaceutical ingredients (APIs), with the White House citing national security risks from foreign supply chain dependencies.
Strategic Reshoring Push
The tariffs, authorized under Section 232 of the 1962 Trade Expansion Act, follow a Commerce Department report warning that 79% of US pharmaceutical facilities rely on overseas materials. Asian producers now face a critical choice: establish US manufacturing operations by Q3 2026 or absorb prohibitive export costs.
Regional Impact Analysis
India's generic drug sector, which supplies 40% of US medications, faces immediate disruption. The Chinese mainland's $12B API export industry to the US is also under scrutiny, though officials emphasize their domestic pharmaceutical innovations meet global standards.
Market Reactions
Tokyo and Mumbai markets saw 3-5% drops in pharmaceutical stocks following the announcement. Analysts predict accelerated manufacturing relocations to Mexico and Canada rather than higher-cost US sites.
